Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs

Abstract

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues).

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of priority under 35 U.S.C. § 119 of U.S. Provisional Application No. 60 / 860,084, filed on Nov. 20, 2006, U.S. Provisional Application No. 60 / 880,742, filed Jan. 17, 2007, U.S. Provisional Application No. 60 / 897,427, filed on Jan. 25, 2007, U.S. Provisional Application No. 60 / 903,529 filed on Feb. 26, 2007, U.S. Provisional Application No. 60 / 926,850 filed Apr. 30, 2007, U.S. Provisional Application No. 60 / 904,473 filed Mar. 2, 2007, U.S. Provisional Application No. 60 / 981,380 filed Oct. 19, 2007, and U.S. Provisional Application 60 / 981,384 filed Oct. 19, 2007, the disclosures of all of which are incorporated by reference herein.FIELD OF THE INVENTION[0002]The present invention relates to a method for treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and ...

AI Technical Summary

Benefits of technology

The present invention provides a method for treating respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis in mammals by administering anti-inflammatory and anti-proliferative drugs such as rapamycin or paclitaxel through various routes such as aerosol inhalation, dry powder inhalation, liquid inhalation, or liquid instillation. The method uses an additive that enhances the absorption of the drug into tissue of the respiratory and sinus system. The additive can be chosen from a variety of compounds such as PEG fatty esters and alcohols, glycerol fatty esters, sorbitan fatty esters, PEG glyceryl fatty esters, PEG sorbitan fatty esters, sugar fatty esters, PEG sugar esters, vitamins and derivatives, aminoacids, multiaminoacids and derivatives, peptides, polypeptides, proteins, quaternary ammonium salts, organic acids, salts, and anhydrides. The method can be used for treating asthma, chronic obstructive pulmonary disease, and chronic sinusitis in premature neonates, children, and adults.

Problems solved by technology

This condition causes shortness of breath.

There are no therapies available today to halt the progression of COPD.

The study concluded, however, that inhaled steroids failed to alter the decline in lung function over time.

This flattens the diaphragm, impairing the ability to inhale and exhale.

Asthma episodes or attacks cause narrowing of the airways, which make breathing difficult.

Asthma attacks can have a significant impact on a patient's life, limiting participation in many activities.

In severe cases, asthma attacks can be life threatening.

Presently, there is no know cure for asthma.

In cases of chronic sinusitis, there is usually tissue damage.

Chronic sinusitis is often difficult to treat successfully, however, as some symptoms persist even after prolonged courses of antibiotics.